Supplementary Material for: Treat-and-Extend Faricimab for Macular Neovascularization in A

A 2026 figshare document presents two clinical case reports on a 1-year follow-up of patients with macular neovascularization secondary to angioid streaks. The report, authored by figshare admin karger, details the treatment outcomes using intravitreal faricimab under a treat-and-extend protocol. The supplementary material is a 215.3 KB DOCX file.

Use Cases

• Analyzing treatment efficacy and safety based on visual acuity and fluid recurrence outcomes described in the cases.
• Studying the application of a treat-and-extend regimen for anti-VEGF therapy in rare ophthalmic conditions.
• Investigating the role of dual-pathway inhibition (faricimab) for managing type 2 macular neovascularization.

Strengths

• Document is licensed under CC-BY-4.0, allowing for flexible reuse.
• Provides specific, longitudinal clinical data over a 1-year follow-up period for two cases.
• Includes detailed patient outcomes such as visual acuity measurements and injection intervals.

Limitations

• Row count and column-level documentation are absent; data structure must be inferred from the text.
• The dataset is very small, consisting of a 215.3 KB document with only two case studies.
• Data may reflect the inherent bias of a case report format, limiting generalizability.

Provenance

Source

figshare

Collection Method

Clinical case report documentation.

Time Range

Covers a 1-year follow-up period for the presented cases.

Freshness

Last updated 2026-05-14 05:55:25.